0 Nanoplasmonics used for monitoring biofilm formation
Researchers from the Okinawa Institute of Science and Technology have developed a method to study biofilm formation, and how it is affected by drugs, with high efficacy.
Browsing: News
0 Positive results for first Phase III study of long-acting, injectable HIV-treatment regimen
ViiV Healthcare has announced positive 48-week results from its Phase III ATLAS study of a long-acting, injectable, two-drug regimen for treating HIV.
0 Rotavirus vaccination has reduced infant deaths in Malawi by a third
The first population-level evidence has proved the rotavirus vaccination saves lives in low-income settings.
0 Ebola vaccination initiated in North Kivu
Vaccination has begun to try and contain the second outbreak of Ebola seen in the Democratic Republic of Congo this year.
0 Can the human microbiome influence rotavirus vaccine response?
New study finds that the oral rotavirus vaccine response could be influenced by changes in the human microbiota.
0 Hepatitis C-infected kidneys safe for transplantation
A study in 20 patients has demonstrated that transplantation followed by antiviral therapy has been successful in patients receiving kidneys from hepatitis C-infected donors.
0 Dengue control: first citywide deployment of Wolbachia
The first citywide deployment of Wolbachia has proved successful, with no dengue cases reported since Wolbachia became established.
0 New trials a game-changer for latent TB treatment
Clinical trial data has proved a novel, short therapy more effective and safe for the treatment of latent tuberculosis than the standard therapy in both adults and children.
0 NIAID warns tick-borne diseases a growing threat
A perspective piece from authors at NIAID has highlighted tick-borne disease as a growing threat in the US, and has emphasized the need for more research.
0 Results from SWORD studies prove the success of a two-drug regimen for HIV
ViiV healthcare has announced results of a 100-week Phase lll program and demonstrated the success of the first two-drug regimen, Juluca®.
